SHANGHAI, November 21, 2011 /PRNewswire-Asia/ -- Sundia MediTech Company Inc., a leading pharmaceutical Contract Research Organization (CRO) in China, announced that the company was named one of the 50 best companies for investment in China in 2011 by Zero2IPO. The news was announced at an October ceremony in Shanghai. This is the third time for Sundia to get this prestigious award after it was previously named in 2007 and 2008.
Zero2IPO-Venture 50 was launched by Zero2IPO Group in 2006. Until now it has become the highest level of enterprise appraisal by venture capitalists in China, and reflects the enterprise with the most potential. The 50 enterprises with the most investment value were selected from a pool of thousands of nominated companies in leading industries by evaluating nominees' business on management team, ownership structure, business model, competitiveness, industry and market, financial situation and forecast, management risks and strategy.
Sundia was founded in 2004 in Shanghai by a group of biotech and pharmaceutical industry veterans from North America. The company has provided integrated R&D outsourcing services to biotech and pharmaceutical clients worldwide. Over the past 7 years, Sundia has successfully established collaborations with over 100 clients in North America, Europe, Japan, Korea and China. Now, Sundia has become a top CRO company in China with 700 employees with operations in Shanghai and Shijiazhuang, the capital city of Hebei Province in Northern China.
Dr. Xiaochuan Wang, Chairman of Sundia attended the ceremony and made a reception speech. "We really appreciate the venture investor for voting Sundia into Venture 50 again. It is recognition of the effort of all of our team members," she acknowledged.
